Shares of Amryt Pharma plc (LON:AMYT – Get Free Report) fell 11.7% on Friday . The stock traded as low as GBX 143 ($1.80) and last traded at GBX 143 ($1.80). 90,726 shares traded hands during mid-day trading, a decline of 81% from the average session volume of 469,552 shares. The stock had previously closed at GBX 162 ($2.04).
Amryt Pharma Stock Performance
The company has a market capitalization of £457.11 million and a PE ratio of -4.33. The stock’s 50 day moving average is GBX 143 and its two-hundred day moving average is GBX 143. The company has a quick ratio of 1.14, a current ratio of 1.80 and a debt-to-equity ratio of 66.05.
Amryt Pharma Company Profile
Amryt Pharma plc, a commercial-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients suffering from serious and life-threatening rare diseases. The company offers Lomitapide for the treatment of homozygous familial hypercholesterolemia; and Metreleptin for the treatment of generalized and partial lipodystrophy.
Further Reading
- Five stocks we like better than Amryt Pharma
- What is a SEC Filing?
- Dave & Buster’s: Is It Time to Make Another Play on This Stock?
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- Why Hershey Stock Has More Room to Run Despite Takeover Rejection
- How to Start Investing in Real Estate
- Texas Instruments: The Old-School Tech Titan Still Delivering
Receive News & Ratings for Amryt Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amryt Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
